Barclays’s West Pharmaceutical WST Stock Holding History

Barclays’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-105,500	Closed	-$34.8M	–	5505
2024 Q2	$34.8M	Buy	+105,500	New	+$37.3M	0.01%	739

Other funds holding WST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Barclays's WST Position: Q2 2026 in Review

Barclays reduced its West Pharmaceutical (WST) stake by 29% in Q2 2026, selling an estimated $31.5M and leaving 246,199 shares worth $88.4M. The position accounts for 0.02% of the portfolio, ranked #537.

Barclays first reported a position in WST in Q2 2013 and has held it in 53 quarters since. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

Barclays held 246,199 shares of West Pharmaceutical worth $88.4M as of Q2 2026.
Barclays sold 102,905 West Pharmaceutical shares in Q2 2026, an estimated $31.5M.
West Pharmaceutical made up 0.02% of Barclays's portfolio in Q2 2026, its #537 holding.
Barclays first reported a position in West Pharmaceutical in Q2 2013 and has held it in 53 quarters since.
831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.